Liana Gercheva
Varna, Bulgaria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Journal: The New England journal of medicine
Published: March 27, 2020
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Journal: Cardiovascular toxicology
Published: December 03, 2019
Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria.
Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
Published: September 28, 2018
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Journal: Cancer medicine
Published: September 17, 2018
PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: March 16, 2017
Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Journal: Journal of thrombosis and haemostasis : JTH
Published: October 31, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Journal: The Lancet. Haematology
Published: February 24, 2016
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
Journal: Thrombosis research
Published: July 14, 2015
Health Care Resource Utilization (HCRU) In Hospitalized Febrile Neutropenia (FN) Patients Treated With Chemotherapy For Solid Tumors (ST) And Hematological Malignancies (HM) In Bulgaria.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Journal: American journal of hematology
Published: October 01, 2014
Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: March 17, 2013
Last Updated: 09/26/2026